{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-121214","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2025-12-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.580723+00:00","generated_at":"2026-05-16T13:14:58.401620+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Humacyte secures up to $77.5M senior secured loan facility from Avenue; draws $40M initial tranche","bullets":["Loan agreement provides $40M upfront, plus $12.5M delayed draw (Oct 2026-Mar 2027) and $25M discretionary tranche (Jul 2027-Jun 2028).","Term loan bears interest at greater of 11.50% or WSJ Prime + 4.50%; matures December 1, 2029.","Lenders may convert up to $2.5M of principal into common stock at 130% of warrant price.","Warrant issued to Avenue exercisable for up to ~$5M worth of common shares at initial price of $1.28, expiring December 2030.","Proceeds used for working capital, general corporate purposes, and to repay existing debt under prior revenue interest purchase agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-121214","json":"https://secwatch.observer/filing/0001104659-25-121214.json","markdown":"https://secwatch.observer/filing/0001104659-25-121214.md","text":"https://secwatch.observer/filing/0001104659-25-121214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000110465925121214/0001104659-25-121214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000110465925121214/tm2533185d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:14:58.401620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1cf6554cc5c4a59a01fafe8343cbbe8f9f17ee0","claim":"Humacyte, Inc. incurred term loan of $77,500,000 with Avenue Venture Opportunities Fund II, L.P. at greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu maturing December 1, 2029.","evidence_excerpt":"On December 15, 2025 (the \"Closing Date\"), Humacyte, Inc. (the \"Company\") and Humacyte Global, Inc. (\"Global\", and together with the Company, the \"Borrowers\"), a wholly-owned subsidiary of the Company, entered into a loan and security agreement (the \"Loan Agreement\") with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders (the \"Loan Agent\") and as lender (\"Avenue\"), which provides for a senior secured term loan facility of up to $77,500,000 in the aggregate that matures on December 1, 2029, consisting of (i) an initial term loan of $40 million (the \"First Tranche Term Loan\"), which was fully funded on the Closing Date, (ii) a $12.5 million delayed draw term loan (the \"Second Tranche Term Loan\") which will be made available between October 1, 2026 and March 31, 2027, subject to the satisfaction of certain revenue, regulatory approvals and liquidity conditions, and (iii) a $25 million delayed draw term loan (the \"Third Tranche Term Lo","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465925121214/0001104659-25-121214-index.htm","confidence":0.98,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$77,500,000"},{"label":"Counterparty","value":"Avenue Venture Opportunities Fund II, L.P."},{"label":"Rate","value":"greater of (i) 11.50% and (ii) the sum of the Wall Street Journal Prime Rate plu"},{"label":"Maturity","value":"December 1, 2029"},{"label":"Event","value":"incurrence"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}